RETA: The real surprise to me wasn't the efficacy, it was the very clean looking safety. There might be safety issues with long term use, but accelerated approval looks possible. If achieved, the drug will be on the market for at least a while before said signal shows, if it does. Admittedly a convincing win for the company and longs, and hopefully for patients, too.
Regards, RockRat
Market Data 
Markets 
AI
